Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1479-1484

  Thirugnanam, Rajasekar ^a   George, Biju ^a   Chendamarai, Ezhil ^a   Lakshmi, Kavitha M ^a   Balasubramanian, Poonkuzhali ^a   Viswabandya, Auro ^a   Srivastava, Alok ^a   Chandy, Mammen ^a   Mathews, Vikram ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Arsenic trioxide; Autologous SCT; Relapsed acute promyelocytic leukemia

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; RETINOIC ACID;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; SCHOOL CHILD; STEM CELL MOBILIZATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70350621606     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.010     Document Type: Article

References (16)

1. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20:57-65.
2. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396-2410.
3. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2005;23:120-126.
4. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113: 1875-1891.
5. Dvorak CC, Agarwal R, Dahl GV, et al. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant. 2008;14:824-830.
6. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
7. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131-134.
8. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504-510.
9. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192-1200.
10. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA Group. Blood. 1999;94:3015-3021.
11. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
12. Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans-retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007; 109:1355-1359.
13. Thomas X, Pigneux A, Raffoux E, et al. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans-retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica. 2006; 91:996-997.
14. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol. 2003; 14:752-757.
15. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94:3315-3324.
16. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.